Pharma and Healthcare Insight provides pharma market intelligence, trend analysis, forecasts and company profiles for the pharma industry on a country-by-country basis across North and South America, Central, Eastern and Western Europe, Asia, the Middle East and Africa. It gives access to the latest independent analysis of market data for the global pharma industry as well as a searchable archive of past articles and data.
ยป To access our 
RSS feed of headlines copy this link to your RSS reader
Industry / Chile
BMI View: Despite Chile's relatively small pharmaceutical market in comparison with other Latin American countries, market growth opportunities will continue to attract investors looking to benefit from the country's resilient private consumption levels.
2010-09-01Industry / Brazil
BMI View: Due to first-mover advantage, EMS is set to dominate the generic atorvastatin market, while Pfizer's partner Eurofarma awaits regulatory approval.
2010-08-31Industry / Mexico
BMI View: Despite significant regional variations, Latin America's regulatory environment will continue to evolve and become increasingly similar to those of developed pharmaceutical...
2010-08-27Industry / China
BMI View: Ovarian cancer is not a major health problem in Asia compared with other malignancies. As the region's economies develop over the medium term, the incidence of ovarian cancer will increase, providing commercial upsides to manufacturers of surgical tools, diagnostics and therapeutics. With respective five-year GDP compound annual compound growth rates (CAGRs) of 10.3% and...
2010-09-01Industry / Australia
BMI View: Australian firm CSL needs to aggressively increase its exposure in emerging markets. The manufacturer of plasma therapeutics has a specialist product portfolio that meets...
2010-08-20Industry / India
BMI Core View: Drugmakers based in emerging markets will increasingly produce hard-to-manufacture pharmaceuticals. Firms in developing countries enjoy low operating costs, but have...
2010-08-19Industry / Turkey
BMI View: A key driver behind Turkey's continued double-digit growth in health expenditure is the country's improved health insurance coverage. The implementation of state-funded health insurance for the lowest earners will make a significant contribution to continued health expenditure growth over the next five years.
2010-09-01Industry / Greece
BMI View: The introduction of a new method to calculate drug prices in Greece will increase some drug prices and reduce others. The industry's reaction to the pricing method has so...
2010-08-27Industry / Bulgaria
BMI View: The outlook for pharmaceutical companies operating in Bulgaria is deteriorating. Disagreements between hospitals and the national funding bodies are a key concern for the...
2010-08-16Industry / United Arab Emirates
We welcome the government's focus on enhancing the UAE's business environment as we believe this will work towards aiding its economic development. The UAE retained its pole position in BMI's Pharmaceuticals & Healthcare Q410 Business Environment Ratings (BERs) for the MEA region. The country's Pharmaceutical Rating of 72.6 is supported by solid scores across all other variables,...
2010-08-31Industry / Kenya
BMI View: Opposition to the Kenyan government's implementation of new, income-dependent rates into citizens' National Health Insurance Fund (NHIF) payments must be addressed. While...
2010-08-23Industry / Australia
BMI View: Aspen Pharmacare Holdings has overpaid for the generic drug business of Sigma Pharmaceuticals. Although the South African drugmaker has gained about a quarter of Australia's...
2010-08-18Industry
BMI View: The design of drugs - both visual and in terms of their administration - will become an increasingly important facet of the drug development process, as the value of a medicine has to be communicated to both patients and healthcare professionals. Patient expectations will rise as the shift towards taking greater responsibility for personal healthcare plays out, driven...
2010-08-27Industry / France
BMI's newest core view is that governments in developed states need to work to maintain the countries' long-term attractiveness as sites for clinical trials, especially as the costs...
2010-08-25Industry / Austria
BMI View: The attractiveness of the Western Europe region to pharmaceutical firms stems from the fact that its countries are key revenue sources for 'big pharma' and particularly for...
2010-08-20
